<DOC>
	<DOCNO>NCT00186316</DOCNO>
	<brief_summary>Patients Multiple myeloma undergone non-myeloablative allogeneic stem cell transplant receive 6 vaccination donor derive dendritic cell combine specific protein produce multiple myeloma .</brief_summary>
	<brief_title>Vaccine Therapy Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells</brief_title>
	<detailed_description>To evaluate feasibility safety vaccination allogeneic idiotype-pulsed dendritic cell follow mixed chimeric allogeneic transplantation multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>1 . For specimen collection idiotype protein development : Must secretory myeloma least .5g/dl serum IgG protein Clinically stage 2 3 multiple myeloma Karnofsky performance status 70 great 2 . For Vaccination : Eligible patient must complete tandem autologous nonmyeloablative allogeneic transplant multiple myeloma Stanford University Medical Center stable disease complete response prevaccine therapy Karnofsky performance status 70 great . ALT AST must &lt; 2X upper limit normal . Total bilirubin &lt; 1.5X upper limit normal . Serum creatinine &lt; 1.5X upper limit normal . Hemoglobin &gt; 9g/dl Patients must HIV negative . Patients must provide sign , inform consent Donor Inclusion Criteria ( allo donor donor use nonmyeloablative transplant ) Age &gt; 17 year HIV negative Must provide sign , inform consent 1 . For specimen collection idiotype protein development : Patients nonsecretory myeloma Severe psychological medical illness Pregnant lactate woman Subjects &gt; Grade I toxicity NCICTC v 3.0 Subjects prognosis &lt; 6 month 2 . For Vaccination : &lt; 75 mg idiotype protein purify patient serum &lt; 25 million allogeneic idiotypepulsed dendritic cell produce vaccination Evidence grade IIIV acute GVHD ( define section 5E ) Patients evidence myeloma disease progression ( define ) Severe psychological medical illness concomitant medication may interfere study determine clinical investigator Patients investigational agent Pregnant lactating woman Patients therapy multiple myeloma chemotherapy drug , immunomodulatory agent treatment multiple myeloma ( e.g . thalidomide ) Any patient two follow immunosuppressive agent dose great indicated single immunosuppressive agent : 1 . Mycophenolate Mofetil ( MMF ) great 1000mg twice day 2 . Prednisone great .5mg/kg/day 3 . Cyclosporine great 300mg/day 4 . Tacrolimus ( FK506 ) great 4mg/day</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>